{"filing":{"accession_number":"0001193125-26-329513","cik":"0001625297","ticker":"INDV","company_name":"Indivior Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-01","primary_document":"d28447d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526329513/d28447d8k.htm"},"events":[{"id":23001,"run_id":20822,"accession_number":"0001193125-26-329513","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Indivior entered into an Agreement and Plan of Merger dated August 1, 2026, with Supernus Pharmaceuticals, whereby Supernus will merge into Indivior's subsidiary Artemis Merger Sub, with Supernus as the surviving company and wholly owned subsidiary of Indivior. The transaction involves a stock-for-stock exchange (1.5401 Indivior shares per Supernus share), a $1 billion special dividend to Indivior shareholders, and a $650 million debt commitment, with the combined company to be renamed Supernus, Inc., and post-closing ownership of approximately 56.5% by Indivior shareholders and 43.5% by Supernus shareholders.","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23134,"accession_number":"0001193125-26-329513","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Item 1.01 discloses entry into an Agreement and Plan of Merger dated August 1, 2026, between Indivior, Artemis Merger Sub (Indivior's subsidiary), and Supernus Pharmaceuticals. The Merger Agreement provides for Merger Sub to merge with and into Supernus, with Supernus as the surviving company and wholly owned subsidiary of Indivior. The transaction involves a stock-for-stock exchange (1.5401 Indivior shares per Supernus share), a $1 billion special dividend to Indivior shareholders, and a $650 million debt commitment. Post-closing, Indivior will be renamed Supernus, Inc., with Indivior shareholders owning ~56.5% and Supernus shareholders ~43.5% of the combined company. This is a material acquisition/change of control transaction requiring stockholder approvals and regulatory clearance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:41:42.188440+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23135,"accession_number":"0001193125-26-329513","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces execution of a Merger Agreement between Indivior and Supernus, with Supernus merging into Indivior's subsidiary (Artemis Merger Sub). The joint press release and supporting voting agreement documents confirm this is a material acquisition/merger transaction. The voting agreement restricts stockholder transfers and voting rights pending stockholder approval, a standard mechanism in M\u0026A transactions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:41:42.188440+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23134,"accession_number":"0001193125-26-329513","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Item 1.01 discloses entry into an Agreement and Plan of Merger dated August 1, 2026, between Indivior, Artemis Merger Sub (Indivior's subsidiary), and Supernus Pharmaceuticals. The Merger Agreement provides for Merger Sub to merge with and into Supernus, with Supernus as the surviving company and wholly owned subsidiary of Indivior. The transaction involves a stock-for-stock exchange (1.5401 Indivior shares per Supernus share), a $1 billion special dividend to Indivior shareholders, and a $650 million debt commitment. Post-closing, Indivior will be renamed Supernus, Inc., with Indivior shareholders owning ~56.5% and Supernus shareholders ~43.5% of the combined company. This is a material acquisition/change of control transaction requiring stockholder approvals and regulatory clearance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:41:42.188440+00:00","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03"},{"id":23135,"accession_number":"0001193125-26-329513","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces execution of a Merger Agreement between Indivior and Supernus, with Supernus merging into Indivior's subsidiary (Artemis Merger Sub). The joint press release and supporting voting agreement documents confirm this is a material acquisition/merger transaction. The voting agreement restricts stockholder transfers and voting rights pending stockholder approval, a standard mechanism in M\u0026A transactions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:41:42.188440+00:00","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03"}]}